Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q3 2022 · 10-Q
Revenue$212.00K$212.00K−74.2% vs Q3 2021 Net Income-$3.06M-$3.06MN/M vs Q3 2021 EPS, diluted—
Operating Income-$3,060,000N/M Operating Cash Flowderived-$2,006,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,020,000N/M Margins · derivedOperating margin-1443.4%−1113.6 pt vs Q3 2021
Net margin-1442.0%−1112.4 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 9, 2022 · 40 d after period end